Weight Loss Fat Loss Hormones Drug Rimonabant for Reduceing Weight

 

Detailed Product Description

 

Weight Loss Fat Loss Hormones Drug Rimonabant CAS 168273-06-1 for Reduceing Weight
 
Quick Details

 

 
Rimonabant Description
 
(1) Rimonabant hydrochloride (SR-141716A) is a potent and selective CB1 cannabinoid inverse agonist/antagonist with a Ki of 1.6 nM, minimal affinity for CB2, and and some GPR55 agonist activity.
 
Rimonabant was developed as an anti-obesity drug because of its appetite suppressant activity, but was taken off the market because of side effects of depression and anxiety.
 
(2) Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.
 
(3) It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.
 
Rimonabant Application
 
Rimonabant is a weight loss drug, Sanofi-Aventis by the French company successfully developed for the treatment of obesity is the first cannabinoid type 1 receptor (CB1) antagonist, by selectively blocking the EC system cannabis Su -1 (cannabinoid-1, CB1) receptors play a role, can significantly reduce weight, reduce waist circumference, reducing risk factors for cardiovascular disease, but also can improve blood lipids and insulin resistance and metabolic syndrome, especially for the existence of clinical obesity or heart disease risk for people.
 
Rimonabant may also be found to be effective in assisting some smokers to quit smoking.Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects.
 
STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy.

COA

 

 
What is Weight Loss Steroids Rimonabant (Acomplia) Used for?
 
Acomplia was studied to be used complementary to diet and exercise to treat obese or overweight patients who suffer from type 2 diabetes and abnormal levels of fat in the blood.
 
Sanofi argued that Acomplia could also prevent the risk of cardiovascular disease. Patients with large waist circumference (102 cm in men and 88 cm in women) were said to most benefit from taking the drug.
 
Rimonabant was submitted to the Food and Drug Administration (FDA) for approval in the United States. However, in 2007, the FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded the French manufacturer Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment for approval. Subsequently, Sanofi-Aventis announced it was suspending the new drug application (NDA) for rimonabant, and that it would resubmit an application at some point in the future.
 
Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects. STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy. According to a Cochrane Collaboration review in 2007, rimonabant "may increase the odds of quitting approximately 11/2-fold".
 
Related product
 

 

Detailed Product Description

 

Weight Loss Fat Loss Hormones Drug Rimonabant CAS 168273-06-1 for Reduceing Weight
 
Quick Details

 

 
Rimonabant Description
 
(1) Rimonabant hydrochloride (SR-141716A) is a potent and selective CB1 cannabinoid inverse agonist/antagonist with a Ki of 1.6 nM, minimal affinity for CB2, and and some GPR55 agonist activity.
 
Rimonabant was developed as an anti-obesity drug because of its appetite suppressant activity, but was taken off the market because of side effects of depression and anxiety.
 
(2) Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.
 
(3) It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.
 
Rimonabant Application
 
Rimonabant is a weight loss drug, Sanofi-Aventis by the French company successfully developed for the treatment of obesity is the first cannabinoid type 1 receptor (CB1) antagonist, by selectively blocking the EC system cannabis Su -1 (cannabinoid-1, CB1) receptors play a role, can significantly reduce weight, reduce waist circumference, reducing risk factors for cardiovascular disease, but also can improve blood lipids and insulin resistance and metabolic syndrome, especially for the existence of clinical obesity or heart disease risk for people.
 
Rimonabant may also be found to be effective in assisting some smokers to quit smoking.Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects.
 
STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy.

COA

 

 
What is Weight Loss Steroids Rimonabant (Acomplia) Used for?
 
Acomplia was studied to be used complementary to diet and exercise to treat obese or overweight patients who suffer from type 2 diabetes and abnormal levels of fat in the blood.
 
Sanofi argued that Acomplia could also prevent the risk of cardiovascular disease. Patients with large waist circumference (102 cm in men and 88 cm in women) were said to most benefit from taking the drug.
 
Rimonabant was submitted to the Food and Drug Administration (FDA) for approval in the United States. However, in 2007, the FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded the French manufacturer Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment for approval. Subsequently, Sanofi-Aventis announced it was suspending the new drug application (NDA) for rimonabant, and that it would resubmit an application at some point in the future.
 
Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects. STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy. According to a Cochrane Collaboration review in 2007, rimonabant "may increase the odds of quitting approximately 11/2-fold".
 
Related product
 

Antacids

Anti Acid Medication,Best Antacid,Antacid Medicine,Antacid Products

NOUVASANT PHARMhealth LTD. , http://www.nouvasant.com